Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study

Mario Cottone, Antonio Craxi, Filippo Mocciaro, Roberto Di Mitri, Marco Giunta, Ambrogio Orlando, Emanuele Orlando, Giulia Rizzuto, Marco Affronti, Marco Mendolaro, Marco Antonio Giunta, Sara Renna

Risultato della ricerca: Review articlepeer review

2 Citazioni (Scopus)

Abstract

Background Adalimumab is effective in the treatment of Crohn's disease. We have already reported data on the efficacy of adalimumab in 110 steroid-dependent patients. At the end of the study 90 patients (64.5%) maintained clinical remission. Aims To assess efficacy and safety of adalimumab after 6 years in patients of the original cohort who responded to treatment. Methods The present study is an extension of the published paper on 90/110 patients. We report results on clinical remission and safety of 6 year maintenance therapy with adalimumab. Results Of the original cohort 90 patients completed the study, 17 were lost to follow-up and 3 died. At the end of follow-up (74.16 ± 10.3 months) 37/90 patients (41%) maintained clinical remission. Of these, 32 (86%) continued adalimumab and 5 (13%) discontinued treatment due to clinical remission and mucosal healing. Of the remaining 53/90 patients, 47 (52%) discontinued adalimumab due to clinical failure and 6 (7%) to adverse events. We obtained endoscopy data in 31/32 patients in clinical remission continuing adalimumab: 11 (36%) did not improve, 6 (19%) worsened, 14 (45%) improved. At univariable analysis no variables were related to treatment outcome. Conclusions This “real life” prospective study shows that adalimumab is a long-term effective and safe maintenance treatment in steroid-dependent Crohn's disease patients.
Lingua originaleEnglish
pagine (da-a)1314-1317
Numero di pagine4
RivistaDigestive and Liver Disease
Volume48
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Entra nei temi di ricerca di 'Six year adalimumab efficacy in steroid-dependent Crohn's disease patients: A prospective single-center real life study'. Insieme formano una fingerprint unica.

Cita questo